Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Grass pollen allergy immunotherapy - Stallergenes Greer plc

Next Previous
Drug Profile

Grass pollen allergy immunotherapy - Stallergenes Greer plc

Alternative Names: 300 IR; 300 IR grass pollen allergen extract - Stallergenes; 300 IR SLIT; Five-grass pollen immunotherapy - Stallergenes; Oralair; Oralair Grasses

Latest Information Update: 26 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Stallergenes SA
  • Developer Endo, Inc.; Stallergenes Greer plc; Stallergenes SA
  • Class Allergens; Antiallergics; Plant allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Seasonal allergic rhinitis
  • No development reported Allergic rhinoconjunctivitis

Most Recent Events

  • 26 Feb 2026 No development reported - Phase-III for Allergic rhinoconjunctivitis in Italy, Denmark, Spain, Slovakia, Czech Republic, Austria, Germany (Sublingual)
  • 23 Apr 2024 Endo International has been acquired and merged into Endo, Inc.
  • 11 Aug 2022 Stallergenes SA completes a phase III trial in Allergic rhinoconjunctivitis in Denmark, Spain, Slovakia, Czech Republic, Germany (Sublingual) prior to August 2022 (EudraCT2005-002501-23)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top